The St. Gallen International Breast Cancer Conference was held virtually this year from March 17 – 20, 2021, and featured talks about many metastatic breast cancer subtypes.
See below to find links to information presented at St. Gallen on hormone-positive, HER2-positive, and triple-negative metastatic breast cancer, as well as de novo MBC, oligometastatic disease, and monitoring treatment response.
Hormone-Positive MBC
- Cancer Therapy Advisor: Fulvestrant Deemed Effective as Later-Line Breast Cancer Treatment
- The Video Journal of Oncology: Circulating Tumor Cell Count-Driven vs. Clinician-Driven 1L Therapy in HR+, HER2- Breast Cancer (video)
HER2-Positive MBC
- Cancer Therapy Advisor: Tyrosine Kinase Inhibitors Combined With Capecitabine Beneficial for HER2-Positive Breast Cancer With Brain Metastases
- Cancer Therapy Advisor: Pertuzumab-Based Dual HER2 Blockade Following Prior Anti-HER2 Therapy for Metastatic Breast Cancer
- The Video Journal of Oncology: Novel Therapies for HER2+ Metastatic Breast Cancer (video)
- The Video Journal of Oncology: Sequencing Novel HER2-Targeted Therapies in Metastatic Breast Cancer (video)
Triple-Negative MBC
- The Video Journal of Oncology: Combined Analyses of PD-L1 and TILs for Therapy Selection in TNBC (video)
- The Video Journal of Oncology: How Can Genomics Inform Treatment Approaches in TNBC? (video)
Other MBC Topics
- Cancer Therapy Advisor: Surgery Boosts Survival in De Novo Metastatic Breast Cancer
- The Video Journal of Oncology: The Potential of Circulating Cell-Free DNA as a Breast Cancer Biomarker (video)
- The Video Journal of Oncology: St. Gallen Consensus Highlights: Ovarian Suppression, Oligometastatic Disease and Radiotherapy (video) The section on oligometastatic disease begins at 2:20.